ClinicalTrials.gg
CompletedNCT05615012Updated Mar 27, 2024

A Study Investigating Interactions Between BMS-986322 and Rosuvastatin, Metformin and Methotrexate in Healthy Participants

A Phase 1 interventional study of BMS-986322 and Rosuvastatin in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-27.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
76
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The aim of this study is to assess the effect of coadministration of multiple oral doses of BMS-986322 with rosuvastatin, metformin, and methotrexate in healthy participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • BMS-986322
  • Rosuvastatin
  • Metformin
  • Methotrexate
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In the opinion of the investigator, a healthy participant, as determined by no deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations.
  • (BMI) of 18.0 kilogram (kg)/meter(m)\^2 to 30.0 kg/m\^2, inclusive, and body weight ≥ 50 kg for males and ≥ 45 kg for females, at screening.
  • A female participant is eligible to participate if she is a woman not of .
  • Female participants must refrain from donating oocytes during the intervention period and for at least 5 half-lives (5 days) after the last dose of study intervention.
  • For Parts 1 and 2 participants must be 18 to 60 years of age.
  • For Part 3 participants must be 18 to 50 years of age.

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness.
  • Any major surgery, including any gastrointestinal (GI) surgery, with the exception of appendectomy, within 90 days of study intervention administration.
  • History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 7 units for women or 14 units for men of alcohol per week (1 unit = 340 mililitre [mL] of beer 5%, 140 mL of wine 12%, or 45 mL of distilled alcohol 40%).
  • Participant must not have a known or suspected immune-mediated disorder, or any history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the participant's immune status.
  • Participant must not have any history or risk for tuberculosis (TB) in participants with current clinical, radiographic, or laboratory evidence of active TB.

Other protocol-defined inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
76 participants (actual)

Study arms

  • Experimental
    Part 1: Rosuvastatin + BMS-986322

    Drug: BMS-986322 · Drug: Rosuvastatin

  • Experimental
    Part 2: Metformin + BMS-986322 + Glucose

    Drug: BMS-986322 · Drug: Metformin · Dietary Supplement: Glucose

  • Experimental
    Part 3: Methotrexate + BMS-986322 + Leucovorin

    Drug: BMS-986322 · Drug: Methotrexate · Drug: Leucovorin

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to 21 days

  2. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC[INF])

    Time frame: Up to 21 days

  3. Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC [0-T])

    Time frame: Up to 21 days

Secondary outcomes

  1. Time of maximum observed plasma concentration (Tmax)

    Time frame: Up to 21 days

  2. Apparent terminal phase half-life (T-HALF)

    Time frame: Up to 21 days

  3. Apparent total body clearance (CLT/F)

    Time frame: Up to 21 days

  4. Number of participants with adverse events (AEs)

    Time frame: Up to 51 days

  5. Number of participants with vital sign abnormalities

    Time frame: Up to 51 days

  6. Number of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to 51 days

  7. Number of participants with physical examination abnormalities

    Time frame: Up to 51 days

  8. Number of participants with clinical laboratory abnormalities

    Time frame: Up to 51 days

07

Study locations

1 site
  • Local Institution - 0001
    Miami, Florida 33136, United States
08

References and documents

Individual participant data

Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Dec 2023, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2022
First posted
Nov 14, 2022
StartActual
Nov 11, 2022
Primary completionActual
Dec 13, 2023
CompletionActual
Dec 13, 2023
Last update
Mar 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05615012
Responsible party
Sponsor
First posted
Nov 14, 2022
Start date
Nov 11, 2022
Primary completion
Dec 13, 2023
Completion
Dec 13, 2023
Last update
Mar 27, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lomedeucitinib · Methotrexate

Start the discussion